Determination of Dose of Antiangiogenic Multitargeted DOVITINIB (TKI258) Plus Paclitaxel in Patients With Solid Tumors
Status:
Terminated
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The investigators plan to study the determination of the dose and the combination of
antiangiogenic effect of dovitinib and cytotoxic activity of weekly paclitaxel in different
types of malignant tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Centro Nacional de Investigaciones Oncologicas CARLOS III
Collaborators:
Hospital Universitari de Bellvitge Hospital Universitario de Fuenlabrada M.D. Anderson Cancer Center